Although not statistically significant, EMV plus d4T plus 3TC appeared to be more synergistic than EMV plus d4T plus ddI. Synergism was also observed with any two-drug combinations, such as EMV plus d4T, EMV plus 3TC, EMV plus ddI, d4T plus 3TC, or d4T plus ddI. The three-drug combina-tions completely suppressed HIV-1 replication for at least 40 days after virus infection. Except for d4T, virus emerged in the presence of every compound alone or some combinations at lower concentrations. Susceptibility tests of the breakthrough viruses to each compound showed that the viruses obtained in the presence of EMV alone and 3TC alone were significantly less susceptible to EMV and 3TC, respectively. These viruses had specific amino acid mutations in their reverse transcriptase.
Highly active antiretroviral therapy (HAART) with reverse transcriptase (RT) inhibitors and protease inhibitors has achieved high-level suppression of viral load in HIV-1infected patients (Carpenter et al., 2000) . However, drugresistant variants of HIV-1 have emerged even in patients treated with two or three drugs, resulting in treatment failure. There are few options of alternative chemotherapy, especially in the case of treatment failure with protease inhibitors. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the third class of compounds with highly potent and selective anti-HIV-1 activity in vitro and in vivo (De Clercq, 1998; Pederson & Pederson, 1999) . Most NNRTIs exert synergistic antiviral activities, when used in combination with nucleoside reverse transcriptase inhibitors (NRTIs). Therefore, the combination of an NNRTI and two NRTIs is considered as a protease-sparing regimen that has comparable efficacy.
Emivirine (EMV, formerly MKC-442) is an NNRTI with highly potent and selective anti-HIV-1 activity in vitro (Baba et al., 1994) . Previous studies have demonstrated that EMV shows synergy with a variety of NRTIs, protease inhibitors and other NNRTIs in vitro (Baba et al., 1994; Hill et al., 1998) . Furthermore, the three-drug combination EMV plus 3TC plus zidovudine (AZT) proved to be highly synergistic for the inhibition of HIV-1 replication in vitro (Piras et al., 1997) . This study also showed that the three-drug combination markedly delayed or even completely suppressed HIV-1 replication in long-term culture of infected cells. Rapid emergence of drug-resistance is a major concern during the treatment with NNRTIs. Resistance is mediated by the amino acid mutations within the NNRTI-binding pocket of HIV-1 RT (De Clercq, 1998) . Among the mutations, the K103N and Y181C mutations confer a high level of resistance to most of the NNRTIs, including EMV (Seki et Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses Introduction al., 1995; Schinazi et al., 2000) . Clearly, EMV must therefore be used in combination with NRTIs or protease inhibitors to achieve the maximum level of HIV-1 inhibition.
EMV is currently undergoing Phase III clinical trials to assess its efficacy in the treatment of HIV-1 infection in adults and children. EMV displays a favourable pharmacokinetic profile and good oral bioavailability (Szczech et al., 2000) . Accordingly, the clinical trials have shown that EMV in combination with NRTIs has high antiviral activity, safety and tolerability in HIV-1-infected patients. When EMV was combined with either stavudine (d4T) plus lamivudine (3TC) or d4T plus didanosine (ddI) and administered to therapy-naive patients, both of the combination regimens produced significant suppression of plasma HIV-1 RNA levels for 48 weeks (Gathiram et al., 13th International AIDS Conference, 2000, Abstract TuPeB3234; Johnson et al., 13th International AIDS Conference, 2000 ). In addition, a recent trial in HIV-1infected pregnant women demonstrated EMV's favourable safety profile in mothers and their infants (Gray et al., 13th International AIDS Conference, 2000, Abstract TuPeB3255) .
In this study, we have evaluated the inhibitory effects of these three-drug combinations on HIV-1 replication and viral breakthrough in cell cultures. Although both EMV plus d4T plus 3TC and EMV plus d4T plus ddI showed equally potent anti-HIV-1 activities, the former combination proved to be more synergistic for inhibition of viral replication and more suppressive to viral breakthrough during long-term culture of infected cells.
Materials and methods
Compounds EMV (6-benzyl-1-ethoxymethyl-5-isopropyluracil) and 3TC were synthesized by Mitsubishi Chemical Corporation (Yokohama, Japan), and d4T and ddI were purchased from Sigma. All compounds were dissolved in dimethyl sulphoxide (DMSO) at a concentration of 20 mM or higher to allow sufficient dilutions to avoid any cytotoxicity.
Cells and virus
MT-4 cells (Miyoshi et al., 1982) were used in the antiviral assays and long-term culture of infected cells. The cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin G, and 100 µg/ml streptomycin. HIV-1 IIIB (Gene Bank accession number: X01762) was used for the infection of MT-4 cells. The virus was propagated and titrated in MT-4 cells and stored at -80°C until use.
Antiviral assays
The activity of the compounds against HIV-1 replication was based on the inhibition of virus-induced cytopatho-genicity in MT-4 cells, as described previously (Baba et al., 1991) . Briefly, the cells (1×10 5 cells/ml) were infected with HIV-1 at a multiplicity of infection (m.o.i.) of 0.02, and were cultured in the presence of various concentrations of the test compounds. After a 4-day incubation at 37°C, the number of viable cells was monitored by the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels et al., 1988) . The cytotoxicity of the compounds was evaluated in parallel with their antiviral activity, on the basis of the viability of mock-infected cells.
Drug-drug interaction
The multiple-drug effect was evaluated by the medianeffect principle and the isobologram method (Chou & Talalay, 1984) . This method involves the conversion of dose-effect curves for each compound and for multiple diluted fixed-ratio combinations of compounds into the median-effect plot. The slope and X-intercept of the plot were used to calculate the combination index (CI). CIs of <1, 1 and >1 indicate synergism, additive effect and antagonism, respectively. All experiments were carried out in duplicate, and repeated at least three times to determine the antiviral activity and CI.
For the analysis of three-drug combinations, the dose-effect relationship of each compound was studied first. The effect of two-drug combinations, such as EMV plus d4T, EMV plus 3TC and d4T plus 3TC, at a constant ratio was then evaluated. The primary CIs were calculated for these two-drug combinations, yielding the primary CIs. Considering EMV plus 3TC as one compound (EMV/3TC), d4T and EMV/3TC were analysed as single compounds and d4T plus EMV/3TC as a two-drug combination. The standard two-drug combination analysis yielded the secondary CIs. The multiplication of each primary and secondary index gave the cumulative index, which described the total synergism or antagonism in the three-drug combination.
Long-term culture of infected cells
MT-4 cells were infected with HIV-1 at a m.o.i. of 0.02. After a 2-h incubation for viral adsorption, the cells were washed thoroughly with culture medium to remove unadsorbed viral particles. The cells (1×10 5 cells/ml) were seeded in a 24-well tray containing various concentrations of the test compounds. After a 4-day incubation at 37°C, the cells were subcultured with fresh culture medium containing appropriate concentrations of the compounds, then incubated. At the time of sub-cultivation, culture supernatants were collected and examined for their p24 antigen level. When the cells were completely destroyed by virusinduced cytopathogenicity, viral RNA was extracted from the culture supernatants, and subjected to nucleotide sequence analysis.
Three-drug combination of RT inhibitors
Determination of nucleotide sequences of RT Viral RNA was extracted from 200 µl of culture supernatants using the RNAzol B (Biotecx Laboratories, Houston, Tex., USA). cDNA was synthesized by adding 2.5 U Monoley murine leukaemia virus RT and 50 pmol/µl random hexamer, and amplified by PCR (Kosalaraksa et al., 1999) . The first round of PCR consisted of 35 cycles with the primer pair SA009 (5′-TTT AAA TTT TCC CAT TAG CCC TAT-3′) and SA015 (5′-ACT CCA TGT ACT GGT TCT TTT AGA-3′), which generated a fragment, including codons 1-272 of HIV-1 RT. These products were further amplified by PCR (25 cycles) with the primer pair 881MF (5′-TGT AAA ACG ACG GCC AGT CCC GGG ATG GAT GGC CCA AAA GTT AAA CAA-3′) and 891MR (5′-CAG GAA ACA GCT ATG ACC GCT AGC CCA ATT CAA TTT TCC CAC TAA-3′), which included the M13 forward and M13 reverse standard primers, respectively. The second round of PCR generated a fragment including codons 16-266 of RT, containing an M13 tail at each end. The amplifed products were isolated from 5% polyacrylamide gels and sequenced directly, using both M13 forward and M13 reverse dye-labelled primers on a model 310 automated DNA sequencer (Applied Biosystems Inc., Foster City, Calif., USA).
Results

Antiviral activity of drug combination
Prior to the three-drug combination experiments, EMV, d4T, 3TC and ddI were examined for their inhibitory effects on HIV-1 replication in MT-4 cells to determine the optimal molar ratio of the compounds for combination. Based on the activity of each compound, the combination ratio of EMV:d4T:3TC:ddI was fixed at 1:100:100:400 (data not shown). For a complete analysis of synergism and antagonism, all compounds and their combinations were tested simultaneously, and concentrations were varied so that the above combination ratio was maintained. Table 1 shows the 50, 70 and 90% effective concentrations (EC 50 , EC 70 and EC 90 , respectively) of each compound alone, in two-drug combinations, and in three-drug combinations. The EC 50 of EMV plus d4T plus 3TC (1:100:100) was 1.0µM, indicating that the concentrations of EMV, d4T and 3TC required to achieve 50% inhibition were approximately 0.005, 0.497 and 0.497 µM, respectively. When this result was compared with that obtained for the two-drug combination d4T plus 3TC (1:1), 1.15 µM d4T and 1.15µM 3TC were required to achieve the same magnitude of inhibition, suggesting the superiority of EMV-containing regimens over those with only NRTIs.
When CIs were calculated, all of the two-drug combinations were additive to synergistic antiviral effects at a level of 50-90% inhibition, except for d4T plus 3TC. The CIs of this combination were 1.1, which indicates an additive to slightly antagonistic effect. This value was constant, irrespective of the inhibition level. Of the two-drug combinations, EMV plus 3TC was found to be the most synergistic, with CIs of 0.71, 0.64 and 0.54 at 50, 70 and 90% inhibition, respectively (Table 1) . When the three-drug combinations EMV plus d4T plus 3TC and EMV plus d4T plus ddI were examined and compared with the twodrug combinations, EMV plus d4T plus 3TC showed an activity comparable to that of EMV plus 3TC. The CI of EMV plus d4T plus 3TC ranged between 0.73 and 0.51, indicating clear synergism at all inhibition levels. EMV plus d4T plus ddI also displayed synergism, yet its activity was weaker than EMV plus d4T plus 3TC (Table 1) . Interestingly, as observed with EMV plus d4T plus 3TC, EMV plus d4T plus ddI showed an activity comparable to that of EMV plus ddI. All of the compounds and their combinations were not cytotoxic to the mock-infected MT-4 cells at the concentrations used in the antiviral assays (data not shown).
Suppression of viral breakthrough during longterm culture
MT-4 cells were infected with HIV-1 and cultured in the presence of every compound alone at a concentration 10-fold greater than the compound's EC 50 . Although the elevation of p24 antigen levels in the culture supernatants was slower in the presence of EMV, 3TC or ddI than in the absence of compound, none of these compounds could suppress HIV-1 replication (Figure 1a ). After an 8or 12-day incubation, the infected cells died because of HIV-1-induced cytopathogenicity. By contrast, no morphological change was observed for the cells cultured in the presence of d4T (data not shown). The p24 antigen level reached a maximum after 4 days, gradually decreased thereafter and disappeared on day 20 (Figure 1a ). Even when the compound was removed from the culture supernatants after 40 days of cultivation, the virus did not emerge again. Similar results were obtained with the twodrug combinations (EMV plus d4T, EMV plus 3TC, EMV plus ddI, and d4T plus 3TC), in which breakthrough viruses did not emerge, even after 40 days ( Figure  1b ). In the case of d4T plus ddI, however, complete suppression of HIV-1 replication was not achieved, and viral breakthrough occurred immediately after removal of the compounds.
Both of the three-drug combinations did not allow the breakthrough of HIV-1 from the infected cells, though marginal and transient elevation of p24 antigen (<1ng/ml) was detected in the culture supernatants on day 4 ( Figure 1c ). In the next experiment, four combinations (d4T plus 3TC, d4T plus ddI, EMV plus d4T plus 3TC, and EMV plus d4T plus ddI) were selected, and whether they could block viral breakthrough at concentrations fivefold greater than their EC 50 was examined. Except for d4T plus 3TC, the test combinations did not suppress viral breakthrough at this concentration (Figure 1d ). The p24 antigen levels reached a peak on days 13-17 for d4T plus ddI and on day 20 for the three-drug combinations. Therefore, MT-4 cells were infected with the breakthrough viruses and cultured with the same compounds at concentrations 10-fold higher than their EC 50 . Under these conditions, all of the combinations could completely block viral breakthrough (Figure 1d ). However, viral breakthrough was observed in the cells exposed to d4T plus ddI, when the compounds were removed from the culture supernatant on day 40.
Drug-susceptibility and RT mutation of breakthrough viruses
To determine whether the breakthrough of HIV-1 was due to the emergence of drug-resistance, breakthrough viruses were propagated once in MT-4 cells and examined for their The cells were infected with HIV-1 and cultured in the presence of compounds at the concentrations that were (a-c) 10-fold and (d) fivefold higher than their EC 50 . Every 4 days, the cells were subcultured, and the culture supernatants were examined for their p24 antigen levels. When the cells were completely destroyed by virusinduced cytopathogenicity (indicated as 0-7), viral RNA was extracted from the culture supernatants and subjected to nucleotide sequence analysis. (d) New MT-4 cells were infected with the breakthrough viruses (5-7) and cultured again with the same compounds in combinations at a concentration 10-fold higher than their EC 50 .(indicated by arrow head), compounds removed from culture supernatants. susceptibility to every compound. As shown in Table 2 , the viruses obtained in the presence of EMV alone and 3TC alone were significantly (215-and > 77-fold) less susceptible to EMV and 3TC, respectively. These viruses had no cross-resistance to other test compounds. Furthermore, reduced susceptibility to the compounds was not identified with the breakthrough viruses in the presence of ddI alone (10×EC 50 ), d4T plus ddI (5 and 10×EC 50 ), and the threedrug combinations (5×EC 50 ).
When the amino acid sequences of the RT genes were analysed, a transition of AAA to AAT at codon 103 was observed with the virus obtained in the presence of EMV alone (data not shown). This mutation leads to an amino acid change from Lys to Asn (K103N). The virus obtained in the presence of 3TC alone had a transition of ATG to ATA at codon 184 (data not shown), leading to an amino acid change from Met to Ile (M184I). The K013N and M184I mutations are known to confer resistance to EMV and 3TC, respectively (Schinazi et al., 2000) . In addition, an amino acid change from His to Tyr was identified at position 221 (H221Y ) of the breakthrough virus in the presence of EMV plus d4T plus 3TC (5×EC 50 ). However, this mutation did not affect the susceptibility to either EMV, d4T, 3TC or ddI (Table 2 ).
Discussion
EMV belongs to the family of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT), which was first identified as a nucleoside analogue with highly specific anti-HIV-1 activity in cell cultures Miyasaka et al., 1989) . Later, the HEPT derivatives were found to be potent non-competitive inhibitors of HIV-1 RT (Baba et al., 1991) . Like other NNRTIs, EMV does not need to be phosphorylated to exert its antiviral activity. EMV showed little or no toxicity towards human mitochondria or human bone marrow progenitor cells. In addition, EMV has a favourable pharmacokinetic profile and good oral bioavailability (Szczech et al., 2000) . These results supported the clinical efficacy studies with HIV-1infected patients.
Initial studies demonstrated that EMV had significant antiviral activity and was well tolerated with few minor adverse effects in HIV-1-infected asymptomatic individuals (Moxaham et al., 6th European Conference on Clinical Aspects and Treatment of HIV Infections, 1997, Abstract 331) . Furthermore, EMV in combination with d4T plus 3TC or d4T plus ddI was recently reported to produce rapid and profound suppression of plasma viral RNA for 48 weeks (Gathiram et al., 13th International AIDS Conference, 2000, Abstract TuPeB3234; Johnson et al., 13th International AIDS Conference, 2000 ). However, amino acid mutations of RT were selected during EMV-containing combination therapy in vivo (Klish et al., 2000) . HIV-1 isolated from patients who experienced virological failure and contained K103N mutation were cross-resistant to the three licensed NNRTIs, namely, nevirapine, delavirdine and efavirenz. This study also showed some difference in resistance profile between EMV plus d4T plus 3TC and EMV plus d4T plus ddI, both of which are currently under Phase III clinical trials.
Our previous and current in vitro studies also show that the three-drug combinations of EMV and NRTIs are synergistically inhibit HIV-1 replication and effectively prevent the emergence of drug-resistant mutants at clinically acceptable concentrations (Piras et al., 1997) . In general, the results of combination and drug-resistant experiments in vitro do not always reflect those obtained in the clinical setting. There are several reasons for this. For instance, the host cells are quite homogeneous in vitro, but various cell (Klish et al., 2000) , was obtained by a few passages of the infected cells exposed to EMV alone (Figure 1a and Table 2 ). This drawback could be overcome with a certain derivative of EMV, since two derivatives were reported to show approximately 30-fold greater inhibitory effect than EMV to the Y181C mutant as well as to the K103N mutant (Hopkins et al., 1999) .
Another interesting observation is that EMV reinforces the activity of NRTI combinations. Except for d4T plus ddI, the two-drug combinations did not allow viral breakthrough at concentrations 10-fold higher than their EC 50 (Figure 1b) . However, the EMV-containing combinations (EMV plus d4T, EMV plus 3TC and EMV plus ddI) seemed to be more suppressive to HIV-1 replication than the NRTI combinations (d4T plus 3TC and d4T plus ddI), as shown by the p24 antigen levels in culture supernatants. On day 12 after virus infection, p24 antigen became undetectable in the culture supernatants of the EMV-containing combinations, but not in those of the NRTI combinations (Figure 1b ). In the case of d4T plus ddI, complete suppression was not observed throughout the culture period, and viral breakthrough occurred immediately after the removal of compounds on day 40. This finding was confirmed by the subsequent experiment with the two NRTI (d4T plus 3TC and d4T plus ddI) and three-drug (EMV plus d4T plus 3TC and EMV plus d4T plus ddI) combinations starting at the concentrations that were fivefold higher than their EC 50 (Figure 1d ). Although d4T plus ddI completely suppressed viral breakthrough after shifting to the twofold higher concentration (10×EC 50 ), a high level of viral replication was observed immediately after the removal of compounds on day 44. Such breakthrough was not observed, when EMV was added to d4T plus ddI.
It has recently been reported that long-term HAART is associated with metabolic side-effects, such as lipodystrophy (Carr et al., 1998; Qaqish et al., 2000) . Development of lipodystrophy is linked to the use of protease inhibitors, though it was also reported in patients receiving only RT inhibitors. In addition, various HAART-associated metabolic disorders, including hyperlipidemia and insulin resistance, have been reported (Carr et al., 1998) . Switching from a protease inhibitor-containing regimen to an EMVcontaining regimen may improve the metabolism of lipids in HIV-1-infected patients, as shown with nevirapine and efavirenz (Martínez et al., 1999; Negredo et al., 40th Interscience Conference on Antimicrobial Agents & Chemotherapy, 2000, Abstract 473) .
In conclusion, the results presented here and currently available in clinical trials clearly indicate that EMV will become an effective component of recommended HAART strategies in patients with HIV-1 infection. In combination with two NRTIs as a first-line therapy, EMV may have the advantage of sparing protease inhibitors for subsequent use.
